The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study | Zendy

Andrew D. Campbell | Zendy; Ze Cong | Zendy; Irene Agodoa | Zendy; Xue Song | Zendy; Diane Martinez | Zendy; Danae Black | Zendy; Carolyn R. Lew | Zendy; Helen Varker | Zendy; Chris Chan | Zendy; Sophie Lanzkron | Zendy

Open Access

The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study

Author(s) -

Andrew D. Campbell,

Ze Cong,

Irene Agodoa,

Xue Song,

Diane Martinez,

Danae Black,

Carolyn R. Lew,

Helen Varker,

Chris Chan,

Sophie Lanzkron

Publication year - 2020

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2020.20009

Subject(s) - medicine , medicaid , stroke (engine) , kidney disease , population , emergency medicine , disease , disease burden , emergency department , end stage renal disease , intensive care medicine , health care , pediatrics , environmental health , mechanical engineering , psychiatry , engineering , economics , economic growth

The management of sickle cell disease (SCD), an inherited, chronic, and multifaceted condition, is associated with considerable health care resource utilization (HRU) and costs, especially for Medicaid. Anemia affects most patients with SCD and correlates with end-organ damage (EOD), such as stroke, chronic kidney disease (CKD), end-stage renal disease (ESRD), and pulmonary hypertension (PH). Limited research has been conducted to quantify the economic burden of EOD among patients with SCD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research